Literature DB >> 17695721

Tumor promotion by tumor-associated macrophages.

Chiara Porta1, Biswas Subhra Kumar, Paola Larghi, Luca Rubino, Alessandra Mancino, Antonio Sica.   

Abstract

Recent years have seen a renaissance of the inflammation-cancer connection stemming from different lines of work and leading to a generally accepted paradigm (Balkwill and Mantovani 2001; Mantovani et al. 2002; Coussens and Werb 2002; Balkwill et al. 2005). An inflammatory component is present in the microenvironment of most neoplastic tissues, including those not causally related to an obvious inflammatory process Cancer-associated inflammation includes: the infiltration of white blood cells, prominently phagocytic cells called macrophages (TAM) (Paik et al. 2004); the presence of polipeptide messengers of inflammation (cytokines such as tumor necrosis factor (TNF) or interleukin-1 (IL-1), chemokines such as CCL2); the occurrence of tissue remodelling and angiogenesis. Chemokines have emerged as a key component of the tumor microenvironment which shape leukocyte recruitment and function (Pollard 2004). Strong direct evidence suggests that cancer associated inflammation promotes tumor growth and progression. Therapeutic targeting of cancer promoting inflammatory reactions is in its infancy, and its development is crucially dependent on defining the underlying cellular and molecular mechanisms in relevant systems.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17695721     DOI: 10.1007/978-0-387-69116-9_5

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  36 in total

1.  Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms.

Authors:  Stacey L Hembruff; Iman Jokar; Li Yang; Nikki Cheng
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

2.  Vascular-leukocyte interactions: mechanisms of human decidual spiral artery remodeling in vitro.

Authors:  Aleah D Hazan; Samantha D Smith; Rebecca L Jones; Wendy Whittle; Stephen J Lye; Caroline E Dunk
Journal:  Am J Pathol       Date:  2010-06-17       Impact factor: 4.307

3.  Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus.

Authors:  J Hughes; P Wang; G Alusi; H Shi; Y Chu; J Wang; V Bhakta; I McNeish; A McCart; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2015-04-16       Impact factor: 5.250

Review 4.  Unfolding the relationship between secreted molecular chaperones and macrophage activation states.

Authors:  Brian Henderson; Samantha Henderson
Journal:  Cell Stress Chaperones       Date:  2008-10-29       Impact factor: 3.667

5.  Macrophage cathepsin K promotes prostate tumor progression in bone.

Authors:  M K Herroon; E Rajagurubandara; D L Rudy; A Chalasani; A L Hardaway; I Podgorski
Journal:  Oncogene       Date:  2012-05-21       Impact factor: 9.867

6.  Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma.

Authors:  Bi Cheng Zhang; Juan Gao; Jun Wang; Zhi Guo Rao; Bao Cheng Wang; Jian Fei Gao
Journal:  Med Oncol       Date:  2010-07-30       Impact factor: 3.064

7.  Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Authors:  Deborah A Knight; Shin Foong Ngiow; Ming Li; Tiffany Parmenter; Stephen Mok; Ashley Cass; Nicole M Haynes; Kathryn Kinross; Hideo Yagita; Richard C Koya; Thomas G Graeber; Antoni Ribas; Grant A McArthur; Mark J Smyth
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

8.  Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis.

Authors:  Jessica S Blackburn; Constance E Brinckerhoff
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

9.  Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer.

Authors:  Heather L Pulaski; Gregory Spahlinger; Ines A Silva; Karen McLean; Angela S Kueck; R Kevin Reynolds; George Coukos; Jose R Conejo-Garcia; Ronald J Buckanovich
Journal:  J Transl Med       Date:  2009-06-19       Impact factor: 5.531

10.  Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma.

Authors:  A Birgersdotter; K R N Baumforth; A Porwit; J Sjöberg; W Wei; M Björkholm; P G Murray; I Ernberg
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.